Company Analysis Asensus Surgical
1. Summary
Advantages
- Price (0.2635 $) is less than fair price (0.3308 $)
- The stock's return over the last year (36.72%) is higher than the sector average (-36.94%).
- Current debt level 9.39% is below 100% and has decreased over 5 years from 33.72%.
Disadvantages
- Dividends (0%) are below the sector average (1.24%).
- The company's current efficiency (ROE=-234.73%) is lower than the sector average (ROE=-80.94%)
Similar companies
2. Share price and performance
2.1. Share price
2.2. News
2.3. Market efficiency
| Asensus Surgical | Healthcare | Index | |
|---|---|---|---|
| 7 days | 0% | 0% | -0.4% |
| 90 days | 3.3% | -43.3% | 8.4% |
| 1 year | 36.7% | -36.9% | 31.3% |
ASXC vs Sector: Asensus Surgical has outperformed the "Healthcare" sector by 73.66% over the past year.
ASXC vs Market: Asensus Surgical has outperformed the market by 5.42% over the past year.
Stable price: ASXC is not significantly more volatile than the rest of the market on "New York Stock Exchange" over the last 3 months, with typical variations of +/- 5% per week.
Long period: ASXC with weekly volatility of 0.7061% over the past year.
3. Summary of the report
4. Fundamental Analysis
4.1. Stock price and price forecast
Below fair price: The current price (0.2635 $) is lower than the fair price (0.3308 $).
Price significantly below the fair price: The current price (0.2635 $) is 25.5% lower than the fair price.
4.2. P/E
P/E vs Sector: The company's P/E (0) is lower than that of the sector as a whole (57.99).
P/E vs Market: The company's P/E (0) is lower than that of the market as a whole (47.41).
4.3. P/BV
P/BV vs Sector: The company's P/BV (2.47) is lower than that of the sector as a whole (9.41).
P/BV vs Market: The company's P/BV (2.47) is lower than that of the market as a whole (22.54).
4.3.1 P/BV Similar companies
4.4. P/S
P/S vs Sector: The company's P/S indicator (9.61) is higher than that of the sector as a whole (4.07).
P/S vs Market: The company's P/S indicator (9.61) is lower than that of the market as a whole (15.1).
4.4.1 P/S Similar companies
4.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (-0.954) is lower than that of the sector as a whole (17.44).
EV/Ebitda vs Market: The company's EV/Ebitda (-0.954) is lower than that of the market as a whole (22.02).
5. Profitability
5.1. Profitability and revenue
5.2. Earnings per share - EPS
5.3. Past profitability Net Income
Yield Trend: Negative and has fallen by -9.83% over the last 5 years.
Accelerating profitability: The return for the last year (0%) exceeds the average return for 5 years (-9.83%).
Profitability vs Sector: The return for the last year (0%) exceeds the return for the sector (-14.25%).
5.4. ROE
ROE vs Sector: The company's ROE (-234.73%) is lower than that of the sector as a whole (-80.94%).
ROE vs Market: The company's ROE (-234.73%) is lower than that of the market as a whole (16.9%).
5.5. ROA
ROA vs Sector: The company's ROA (-129.57%) is lower than that of the sector as a whole (6.66%).
ROA vs Market: The company's ROA (-129.57%) is lower than that of the market as a whole (6.57%).
5.6. ROIC
ROIC vs Sector: The company's ROIC (0%) is lower than that of the sector as a whole (15.68%).
ROIC vs Market: The company's ROIC (0%) is lower than that of the market as a whole (9.31%).
7. Dividends
7.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '1.24%.
7.2. Stability and increase in payments
Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.
7.3. Payout percentage
Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
